OncLive Peer Exchange®

Yi-Bin Chen, MD; Nelson J. Chao, MD, MBA; Hannah Choe, MD; and Sophie Paczesny, MD, PhD, review updates in the diagnosis and treatment of graft-vs-host disease.

A panel of experts discuss myeloproliferative neoplasms, focusing primarily on myelofibrosis, and share their experiences treating these diseases.

A panel discussion on changing treatment landscape of diffuse large B-cell lymphoma (DLBCL) and how new data from ASH 2021 on CAR-T therapies and antibody-drug conjugate are likely to change frontline treatment and sequencing of therapies in relapsed and refractory DLBCL going forward.

Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.

Recommendations for treating 2 clinical cases of metastatic breast cancer with antibody-drug conjugates based on supporting data and their adoption into clinical practice.

Funding from Daiichi Sanyko. Content Developed Independently by OncLive.

Expert perspectives on updates in EGFR-mutant resectable and advanced non–small cell lung cancer that were presented at key conferences in 2021 and how they have impacted the treatment landscape.

Experts in hematology/oncology review recent updates in the treatment of multiple myeloma presented at key conferences and share insight on the impact on clinical practice.

Medical oncologists and endocrinologists discuss approaches to the management of patients with differentiated thyroid cancer.

A panel of experts discuss basal cell carcinoma and cutaneous squamous cell carcinoma therapeutic agents in depth as they analyze clinical case scenarios.

Experts in gastroenterology provide insight on various case studies and the optimal treatment approaches for the management of HCC.

An international perspective pertaining to treatment advances in HER2-positive metastatic breast cancer and how to best apply data from ESMO 2021 into daily practice.

Experts in lung cancer provide insight on recent data from the 2021 ASCO, ESMO, and IASLC World Conference on Lung Cancer conferences and review updates in the treatment landscape for non-small-cell lung cancer and small cell lung cancer.

Expert panelists share insight on the current treatment landscape of cervical cancer, locally advanced and metastatic, in light of recent clinical studies and drug approvals.

Updates in the prevention and management of chemotherapy-induced neutropenia, specifically in breast cancer, with special considerations for the impact of new data on practice patterns.

A discussion on how to apply updated data from ESMO 2021 to treatment decisions for patients with HR+/HER2- advanced breast cancer.

Reactions to treatment advances and new FDA approvals in prostate cancer, and insight regarding the valuable role that precision medicine plays in genitourinary oncology.

Mark Socinski, MD, Gilberto Lopes, MD, Afsaneh Barzi, MD, PhD, and Jack West, MD, discuss the balance of using innovative cancer therapies with disruptive drug prices to make the therapies more widely available.

An overview of data supporting exciting developments in hepatocellular carcinoma using systemic therapy in various treatment settings.

Key opinion leaders review clinical cases in systemic mastocytosis, focusing on therapeutic options and diagnostic criteria.

A panel of experts in thoracic oncology discuss the potential impact of recent clinical data on treatment of small cell lung cancer.

A discussion about several topics pertaining to the treatment of CLL including the latest research in the field and the impact of recent clinical trial data on making treatment decisions for your patients.

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss modern approaches to the management of multiple myeloma and review recent data presented at the 2021 ASCO Annual Meeting.

The latest research and impact of recent clinical trials on treatment selection using erythropoiesis stimulating and hypomethylating agents for myelodysplastic syndrome.

A discussion regarding the potential implications of treating renal cell carcinoma based on recent clinical trial data and key presentations from the 2021 ASCO virtual meeting.

Systemic treatment options available for HER2+ metastatic breast cancer based on recent clinical trial data and abstract presentations from the ASCO 2021 virtual meeting.

Experts discuss advancements in the development of targeted agents in oncogene-driven non–small cell lung cancer, highlight the results from key clinical trials presented at the American Society of Clinical Oncology 2021 Annual Meeting, and provide insights on how these findings may support treatment decision making in an era of precision medicine.

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss systemic therapy and recent clinical trial data presented at the 2021 ASCO Annual Meeting for hormone receptor-positive breast cancer.

The latest research and impact of recent clinical trials on treatment selection using immunotherapy-based regimens for metastatic non–small cell lung cancer (NSCLC), consolidation immunotherapy in stage III disease, and perioperative regimens with immunotherapy in resectable NSCLC.